Corona's indigenous vaccine Covaxin may be delayed further in getting international recognition. The World Health Organization (WHO) has questioned some more technical information from Bharat Biotech. In such a situation, people going abroad, especially students (who have taken Covaxin) may have to wait longer. The WHO has sought some technical information from Covaxin from the Indian company Bharat Biotech.
Bharat Biotech has already provided all the data related to the vaccine to the WHO for Emergency Use Authorization (EUA). Recently, the central government had said that the WHO can give its approval to Covaxin anytime soon. According to a report by news agency ANI, Dr. Bharti Praveen Pawar, Union Minister of State in the Ministry of Health had said last Friday, "There is a process to submit documents for approval. Covaxin will soon get WHO approval for emergency use.
Earlier Britain also recognized Covishield but added some conditions for Indians. India also expressed displeasure over this. According to the new rules, Indians who have received both doses of the Covishield vaccine will still have to remain in quarantine for 10 days on arrival in the UK and will also have to undergo tests. Indian citizens have described this decision of Britain as racial. Britain says that they have no problem with those who have installed Covishield. They cannot trust India's vaccine certificate.
The UK government issued a rule on 18 September that if you have been vaccinated in Africa, South America or the United Arab Emirates, India, Turkey, Jordan, Thailand, and Russia, you will be considered unvaccinated the UK and 10 days upon arrival in the UK. The quarantine will have to be done and tests will have to be done.
On the other hand, Bharat Biotech has also completed the third phase trial of Covaxin on children. The company has said that it will hand over the third phase data to DGCI next week. At present, the data of the third phase is being analyzed. At the same time, the Serum Institute of India is also conducting the second-third phase trial of Kovavax on children aged 2 to 12 years.
Like and Follow us on :
